Amanta Healthcare Limited (AMANTA)
Announcement under Reg 30- Press Release
Press Release - Q1FY27
- Revenue 68.8 Cr +5.4% y-y; EBITDA 15.2 Cr (margin 22%, -200 bps y-y); PAT 3.3 Cr -5.6% y-y
- Revenue growth driven by improved product mix and better price realizations
- EBITDA margin declined due to higher raw material, employee and operating costs
- PAT impacted by higher finance costs from new Solar Term Loan
- Capacity expansion with Steriport plant commissioning by Q2FY27 and SVP expansion by Q4FY27
- Solar power plant to enhance cost efficiency and operating leverage
- CMD Bhavesh Patel confident of scaling growth and profitability in domestic and export markets
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AMANTA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AMANTA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Amanta Healthcare Limited
Important.
The summary above is generated automatically from Amanta Healthcare Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.